Introduction
============

Web-based self-reporting of symptoms is a growing field and has been used to improve survival in oncology \[[@ref1],[@ref2]\]; it can be used as a participatory surveillance tool for coronavirus disease (COVID-19) or other influenza-like illnesses as well \[[@ref3],[@ref4]\]. We thought of applying the same technology to optimize patient triage for COVID-19 patients in France and alleviate the burden on emergency call centers. A self-assessment and participatory surveillance website \[[@ref5]\] was developed and launched during the growing phase of the COVID-19 epidemic in France in March 2020. Our objective was to determine if self-reported symptoms could help monitor outbreak dynamics in France. We report here the analysis of the first 13 days of web application usage.

Methods
=======

Users were recruited via national media campaigns in France, including social media, radio, and magazine campaigns, between March 17-29, 2020. Participants were recruited through the maladiecoronavirus.fr website \[[@ref5]\]. Respondents provided information on sociodemographic data, zip code, and coexisting disorders anonymously. They were asked about nine symptoms associated with possible COVID-19 infection---fever (body temperature \>37.7°C), unusual cough, shortness of breath, sore throat, muscle aches, diarrhea, anorexia, and asthenia. Anosmia, a loss of the sense of smell, was added on March 21, 2020. Following symptom reporting, a notification was sent, recommending the user either to stay at home and use the website again in case of evolving symptomatology (self-monitoring), or to contact a general practitioner (GP), or to call an emergency number if they reported dyspnea or anorexia. A questionnaire was built according to Chinese reports and French experience \[[@ref6]\]. The website was not considered a medical device by regulatory authorities since no tracking was performed and data were anonymous. We compared the distribution of web-based, self-reported symptoms to that of hospitalized COVID-19 patients according to Ministry of Health reports. Spearman correlation coefficients were used for statistical analysis.

Results
=======

Between March 17-29, 2020, the website was accessed 4,126,789 times; 3,799,535 electronic questionnaires were filled out; and 2,477,174 users had at least one out of the nine symptoms included in the questionnaire ([Figure 1](#figure1){ref-type="fig"}). In total, 1,322,361 (34.8%) participants reported no symptoms. The remaining patients (median age 37 years; range 15-99 years) were directed to self-monitoring (858,878, 22.6%), GP visit or teleconsultation (1,033,922, 27.2%), or an emergency phone call (584,374, 15.4%).

Of all symptomatic patients, anosmia was reported by 17.1% (325,910/1,903,741), fever was reported by 33.5% (828,952/2,477,174), and cough by 61.2% (1,515,557/2,477,174). Emergency warning signs (dyspnea or complete anorexia) were reported by 39.1% of participants with anosmia (n=127,586) versus 22.7% of participants without anosmia (n=1,597,289; *P*\<.001; [Table 1](#table1){ref-type="table"}). Anosmia and fever and/or cough were correlated with COVID-19--related hospitalizations (Spearman correlation coefficients=0.87 and 0.82, respectively; *P*\<.001 for both; [Figure 2](#figure2){ref-type="fig"}).
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###### 

Users characteristics.

  ------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                         Value (n=2,477,174^a^)                               
  ------------------------------------------------------ ---------------------------------------------------- ------------------
  Age (years), average (range), median                   39.12 (15-99), 37                                    

  Sex                                                    ---^b^                                               

  **Body mass index (kg/m^2^)**                          \                                                    

  \                                                      ≥30                                                  436,609 (17.6)

  \                                                      \<30                                                 2,040,555 (82.4)

  **Comorbidities**                                      \                                                    

  \                                                      Cardiovascular disease / uncontrolled hypertension   401,888 (16.2)

  \                                                      Diabetes                                             78,354 (3.2)

  \                                                      Malignancy                                           72,577 (2.9)

  \                                                      Pulmonary disease                                    243,247 (9.8)

  \                                                      Chronic kidney disease                               11,333 (0.5)

  \                                                      Chronic liver disease                                36,677 (1.5)

  \                                                      Pregnancy                                            40,766 (1.6)

  \                                                      Immunodepression                                     135,624 (5.5)

  \                                                      Immunosuppressive ongoing therapy                    70,927 (2.9)

  **Reported symptoms**                                  \                                                    

  \                                                      Fever (body temperature greater \>37.7°C)            828,952 (33.5)

  \                                                      Cough                                                1,515,557 (61.2)

  \                                                      Dyspnea                                              658,442 (26.6)

  \                                                      Asthenia                                             1,155,297 (46.6)

  \                                                      Complete anorexia                                    103,122 (4.2)

  \                                                      Sore throat or muscle aches                          1,837,286 (74.1)

  \                                                      Diarrhea                                             497,665 (20.1)

  \                                                      Anosmia or dysgeusia^c^                              325,910 (17.1)

  **Patient triage after questionnaire completion^d^**   \                                                    

  \                                                      No symptoms                                          1,322,361 (34.8)

  \                                                      Self-monitoring                                      858,878 (22.6)

  \                                                      General practitioner / phone call                    1,033,922 (27.2)
  ------------------------------------------------------------------------------------------------------------------------------

^a^Symptomatic patient (reported at least one symptom).

^b^Sex was not asked to protect the identity of the user.

^c^Anosmia was reported from March 21, 2020; the number of symptomatic patients during this period was 1,903,741.

^d^Denominator is N=3,799,535 (all respondents; symptomatic or not).
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Discussion
==========

This study suggests that self-reported symptoms of COVID-19 are correlated with COVID-19--related hospitalizations and that anosmia may be strongly associated with COVID-19. This could be explained by a greater specificity compared to other reported symptoms that could result from other respiratory viruses \[[@ref7],[@ref8]\]. Limitations include lack of medical assessment and virological confirmation of COVID-19 and comparison of application-retrieved data with a distinct set of data from the Ministry of Health reports on hospitalizations. Self-checking application data could be a relevant tool to monitor the dynamics of an outbreak and thus can be a real-time health system response to the epidemic.
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